钠–葡萄糖共转运蛋白2抑制剂改善病理性心脏重塑的研究进展  

Progress in the Treatment of Pathological Cardiac Remodeling with Sodium-Glucose Cotransporter 2 Inhibitors

作　　者：宋琦[1] 凌智瑜[1] 

机构地区：[1]重庆医科大学附属第二医院心血管内科,重庆

出　　处：《临床医学进展》2024年第8期429-438,共10页Advances in Clinical Medicine

摘　　要：心脏重塑是心脏在持续性压力、代谢等刺激下发生的适应性形态结构变化过程,其中病理性心脏重塑是心血管不良事件独立危险因素。新型降糖药物钠–葡萄糖协同转运蛋白-2 (sodium-glucose cotransporter 2, SGLT2)抑制剂除了能够降低容量负荷、减少心血管死亡及住院风险外,还展现出改善心脏结构和功能、逆转心脏重构的潜力。本文旨在对SGLT2抑制剂在改善心脏重塑方面的研究进展进行综述。Cardiac remodeling, a process of adaptive morphological and structural alterations in the heart triggered by sustained stress, metabolic, and other stimuli, among which pathological cardiac remodeling serves as an independent predictor of adverse cardiovascular outcomes. Recently, novel hypoglycemic agents, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, have emerged as potential therapeutics that not only alleviate volume overload but also reduce the risk of cardiovascular mortality and hospitalization. Additionally, these agents exhibit promising effects in improving cardiac structure and function, as well as reversing pathological cardiac remodeling. This article aims to comprehensively review the progress made in investigating the therapeutic benefits of SGLT2 inhibitors in ameliorating cardiac remodeling.

关 键 词：钠–葡萄糖共转运蛋白2抑制剂 心脏重塑 心力衰竭 分子机制 

分 类 号：R54[医药卫生—心血管疾病]